Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5161 studies found for:    Open Studies | "Immune System Diseases"
Show Display Options
Rank Status Study
21 Unknown  Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status
Conditions: Inflammatory Disorder of Immune System;   Sepsis
Interventions: Other: blood sample collection;   Drug: Midazolam;   Drug: Morphine;   Procedure: Sedation interruption
22 Recruiting Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
Condition: Chronic GVHD After HCT for Cancer or Immune Disease
Intervention: Other: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
23 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
24 Recruiting Participation in a Research Registry for Immune Disorders
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
25 Recruiting Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments
Conditions: Rheumatoid Arthritis;   Osteoarthritis;   Systemic Lupus Erythematosus;   Sjogren's Syndrome;   Scleroderma;   Spondylitis;   Gout;   Spinal Disease;   Chondrocalcinosis
26 Recruiting Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
Conditions: Primary Immunodeficiency (PID);   Secondary Immunodeficiency (SID);   Neurological Autoimmune Disease
Intervention: Other: Immunoglobulin G (IgG)
27 Recruiting Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Conditions: Immunosuppression;   Periodontal Disease;   Healthy Subjects;   Healthy Volunteer
28 Recruiting ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Condition: Acute Lymphoblastic Leukemia
Interventions: Genetic: Pharmacogenomics;   Other: Busulfan plasma level measurements
29 Recruiting Severe Asthma Research Program - University of Virginia
Condition: Asthma
30 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
31 Recruiting A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: KD025
32 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
33 Recruiting Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Condition: Primary IgA Nephropathy
Interventions: Drug: Hydroxychloroquine Sulfate;   Drug: Valsartan
34 Recruiting A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Bendamustine
35 Recruiting Childhood Asthma Perception Study
Conditions: Asthma;   Childhood Asthma
Interventions: Behavioral: PEF Feedback;   Behavioral: Control Feedback
36 Recruiting Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: Entospletinib;   Drug: Placebo;   Drug: Systemic Corticosteroids
37 Not yet recruiting Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-05)
Condition: Relapsed, Diffuse Large B-cell Lymphoma
Intervention: Drug: Betalutin
38 Not yet recruiting Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: Betalutin with HH1 pre-dosing;   Drug: Betalutin with Rituximab pre-dosing
39 Recruiting Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular, Grade 3b;   Follicular Lymphoma, Grade 3b
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide
40 Recruiting Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Biological: HYQVIA;   Biological: 0.25% albumin placebo solution with rHuPH20;   Biological: IGIV

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years